Laboratory information management system for COVID-19 non-clinical efficacy trial data
Authors
Suhyeon Yoon ; Hyuna Noh ; Heejin Jin ; Sungyoung Lee ; Soyul Han ; Sung-Hee Kim ; Jiseon Kim ; Jung Seon Seo ; Jeong Jin Kim ; In Ho Park ; Jooyeon Oh ; Joon-Yong Bae ; Gee Eun Lee ; Sun-Je Woo ; Sun-Min Seo ; Na-Won Kim ; Youn Woo Lee ; Hui Jeong Jang ; Seung-Min Hong ; Se-Hee An ; Kwang-Soo Lyoo ; Minjoo Yeom ; Hanbyeul Lee ; Bud Jung ; Sun-Woo Yoon ; Jung-Ah Kang ; Sang-Hyuk Seok ; Yu Jin Lee ; Seo Yeon Kim ; Young Been Kim ; Ji-Yeon Hwang ; Dain On ; Soo-Yeon Lim ; Sol Pin Kim ; Ji Yun Jang ; Ho Lee ; Kyoungmi Kim ; Hyo-Jung Lee ; Hong Bin Kim ; Jun Won Park ; Dae Gwin Jeong ; Daesub Song ; Kang-Seuk Choi ; Ho-Young Lee ; Yang-Kyu Choi ; Jung-Ah Choi ; Manki Song ; Man-Seong Park ; Jun-Young Seo ; Ki Taek Nam ; Jeon-Soo Shin ; Sungho Won ; Jun-Won Yun ; Je Kyung Seong
COVID-19 ; Data ; Laboratory information management system ; Non-clinical ; SARS-CoV-2
Abstract
Background: As the number of large-scale studies involving multiple organizations producing data has steadily increased, an integrated system for a common interoperable format is needed. In response to the coronavirus disease 2019 (COVID-19) pandemic, a number of global efforts are underway to develop vaccines and therapeutics. We are therefore observing an explosion in the proliferation of COVID-19 data, and interoperability is highly requested in multiple institutions participating simultaneously in COVID-19 pandemic research.
Results: In this study, a laboratory information management system (LIMS) approach has been adopted to systemically manage various COVID-19 non-clinical trial data, including mortality, clinical signs, body weight, body temperature, organ weights, viral titer (viral replication and viral RNA), and multiorgan histopathology, from multiple institutions based on a web interface. The main aim of the implemented system is to integrate, standardize, and organize data collected from laboratories in multiple institutes for COVID-19 non-clinical efficacy testings. Six animal biosafety level 3 institutions proved the feasibility of our system. Substantial benefits were shown by maximizing collaborative high-quality non-clinical research.
Conclusions: This LIMS platform can be used for future outbreaks, leading to accelerated medical product development through the systematic management of extensive data from non-clinical animal studies.